

Usage of Mineralocorticoids and Isotonic Crystalloids in Subarachnoid Hemorrhage Patients in the United States

Akshatkumar M. Mistry, MD¹; Janki Naidugari, BS;² Jocelyn Craven, MPH;³ Logan Williams, MPH;³ Jonathan Beall, PhD;³ Pooja Khatri, MD;⁴ Joseph P. Broderick, MD;⁴ Todd W. Rice, MD, MSc;⁵ Hooman Kamel, MD;⁶ William Mack, MD;⁷

¹Department of Neurosurgery, University of Louisville, Louisville, KY, USA. ²School of Medicine, University of Louisville, Louisville, KY, USA. ³Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. ⁴Departments of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, OH, USA. ⁵Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ⁶Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY, USA. ⁷Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Corresponding Author: Akshatkumar M. Mistry, MD

Department of Neurological Surgery, 220 Abraham Flexner Way, 15th Floor,
University of Louisville, Louisville, KY 40202
Telephone: 502-407-3226; Fax: 502-582-7477; E-mail: axitamm@gmail.com

Funding: NINDS U01NS086872 and U01NS087748

Short title: Mineralocorticoid and fluids use in aSAH in the US

Keywords: Subarachnoid hemorrhage; Fludrocortisone; Critical Care; Mineralocorticoid; Fluids

Disclosures: None

26 **ABSTRACT**

27 **Background:** The usage rates of mineralocorticoids (fludrocortisone) to treat hyponatremia and
28 isotonic crystalloids (saline and balanced crystalloids) to maintain intravascular volume in
29 patients with aneurysmal subarachnoid hemorrhage (aSAH) patients across the United States
30 are unknown.

31 **Methods:** We surveyed National Institute of Neurologic Disorders and Stroke (NINDS)
32 StrokeNet sites, which are mostly large, tertiary, academic centers, and analyzed subarachnoid
33 hemorrhage encounters in the Premier Healthcare Database that is representative of all types of
34 hospitals and captures about 20% of all acute inpatient care in the United States.

35 **Results:** Although mineralocorticoids are used by 70% of the NINDS StrokeNet sites in aSAH
36 patients, it is used in less than 25% of the aSAH encounters in the Premier Database. Although
37 saline is ubiquitously used, balanced crystalloids are increasingly used for fluid therapy in aSAH
38 patients. Its use in the NINDS StrokeNet sites and the Premier Healthcare Database is 41% and
39 45%, respectively.

40 **Conclusions:** The use of mineralocorticoids remains low, and balanced crystalloids are
41 increasingly used as fluid therapy in aSAH patients. The effectiveness of mineralocorticoids and
42 balanced crystalloids in improving outcomes for aSAH patients must be rigorously tested in
43 randomized clinical trials.

44

45 INTRODUCTION

46 Inpatient and overall mortality of patients with aneurysmal subarachnoid hemorrhage
47 (aSAH) are 20% (1-3) and 40%, respectively (4). The high mortality rate results from life-
48 threatening neurological sequelae and non-neurological complications, like fatal volume loss
49 from kidney-drive natriuresis (cerebral salt wasting) (5-7). Ensuing hyponatremia and polyuria
50 can be exceptional in aSAH patients, requiring treatment of hyponatremia and intravenous fluids
51 to maintain their intravascular volume (8-10).

52 The 2023 American Heart Association aSAH guidelines recommend that “the use of
53 mineralocorticoids is reasonable to treat natriuresis and hyponatremia” (11). Specifically,
54 fludrocortisone is established to reduce natriuresis, hyponatremia, and polyuria in aSAH
55 patients (9). A meta-analysis of the studies shows that mineralocorticoid use lowers the rate of
56 symptomatic vasospasm in aSAH patients (9).

57 Maintaining intravascular volume is critical in aSAH patients. There are several options
58 for maintenance intravenous fluid therapy: hypotonic or isotonic crystalloid solutions or colloid
59 solutions. The Neurointensive Care consensus and clinical practice guidelines for stroke
60 (including aSAH) and traumatic brain injury *strongly* recommend using crystalloids and against
61 using colloid fluids (12). Given the importance of tonicity to control cerebral edema, isotonic
62 rather than hypotonic crystalloids are most commonly used for intravenous maintenance fluid
63 therapy.

64 The usage rates of fludrocortisone and different isotonic crystalloids across the United
65 States are unknown. Efforts to understand the impact of these interventions are better informed
66 with this information. In this short communication, we report the usage rates of fludrocortisone
67 and isotonic crystalloids (saline or balanced crystalloids) from a survey of the National Institute
68 of Neurologic Disorders and Stroke (NINDS) StrokeNet sites (which are mostly large, tertiary,
69 academic centers) and in the Premier Healthcare Database.

70

71 **METHODS**

72 **NINDS StrokeNet Site Survey**

73 We surveyed the NINDS StrokeNet sites in May 2023. Within the 27 regional
74 coordinating centers, there are 441 clinical performing sites in the StrokeNet network. The
75 survey was filled out by the PIs at 87 sites (19.7% response rate). The following questions were
76 asked:

- 77 - In which type of intensive care unit (ICU) does an SAH patient typically get admitted at
78 your site?
 - 79 ○ Dedicated neuro ICU
 - 80 ○ Other ICU
- 81 - Is the critical care of patients with aneurysmal SAH managed by a "closed" team? (i.e.,
82 only one team placing orders for critical care management, i.e., "closed ICU")
 - 83 ○ Yes
 - 84 ○ No
- 85 - Are plasma electrolytes assessed daily in SAH patients admitted to ICU?
 - 86 ○ Yes
 - 87 ○ No
- 88 - How does your site treat hyponatremia in aneurysmal SAH patients? Check all that
89 apply.
 - 90 ○ Mineralocorticoid (i.e., fludrocortisone or hydrocortisone)
 - 91 ○ Enteral salt supplementation
 - 92 ○ Hypertonic saline
 - 93 ○ Desmopressin (DDVAP)
 - 94 ○ Other (specify)

- 95 - Does your site have a protocol for treating hyponatremia that all providers follow?
- 96 o Yes, all providers follow our site-specific protocol for treating hyponatremia.
- 97 o No, there is likely provider-dependent variation.
- 98 - What crystalloid is used for intravenous fluid therapy in SAH patients at your site? Check
- 99 all that apply.
- 100 o Saline (0.9% NaCl)
- 101 o Balanced crystalloids (Plasma-Lyte or lactated Ringer's)
- 102 o Other (specify)

103

104 **Premier Healthcare Database**

105 We analyzed the service-level, all-payer Premier® Healthcare Database (PINC AI™ /

106 Premier Inc., Charlotte, NC) of electronic health records and hospital billing data from 2010 to

107 2020. It is a population-based research database with information from over 900 United States

108 hospitals and health systems. It includes real-world data from at least 45 states in the United

109 States and the District of Columbia, and it is estimated to capture approximately 20% of all

110 acute inpatient care in the United States. It is arguably representative with respect to hospital

111 size, geographic region, location (urban/rural) as well as profit, governmental, and teaching

112 status. Among the data, it includes diagnoses and treatments, such as procedures and

113 medications. Thus, we retrieved inpatient encounters from the Premier Healthcare Database

114 using both the International Classification of Diseases (ICD) 9 and 10 diagnoses codes for

115 subarachnoid hemorrhage (430 and I60) and who also had one or more of the following billing

116 CPT codes for a procedure to treat subarachnoid hemorrhage (61624, 75894, or any code from

117 61680 to 61711). From these encounters, the total number of encounters with one or more

118 orders of fludrocortisone, saline (normal or 0.9%), and balanced crystalloids (Plasma-Lyte or

119 lactated Ringer's) was counted.

120

121 **RESULTS**

122 **NINDS StrokeNet Site Survey**

123 Three of the 87 NINDS StrokeNet sites that responded to the survey did not answer
124 questions about ICU characteristics (Figure 1). Of the 84 responses, 75 indicated that aSAH
125 patients at their sites were admitted to a dedicated neurological ICU. The ICU is “closed” in 52
126 sites. In sites where it is “open”, the critical care and neurosurgery teams jointly manage the
127 critical care needs of the patients. All but one site (N=83) that responded assess plasma
128 electrolytes daily.

129 All 87 sites responded to the question of hyponatremia treatment. From the most to least
130 common, treatments used for hyponatremia were hypertonic saline (N=77, 88.5%),
131 mineralocorticoid (N=61, 70.1%), enteral salt supplementation (N=59, 67.8%), and DDVAP
132 (N=20, 23%). Other treatments included fluid restriction (N=5, 5.7%) and urea (N=1). Sixty-three
133 (72.4%) sites do not have a protocol to treat hyponatremia in aSAH patients.

134 For intravenous fluid therapy, 77 (88.5%) sites use saline, and 36 (41.4%) use balanced
135 crystalloids. Forty-three (49.4%) sites only use saline, and 4 (4.6%) sites only use balanced
136 crystalloids. One site reported using sodium acetate.

137

138 **U.S.-Wide Use of Fludrocortisone and Fluids**

139 A total of 20,699 encounters of procedurally treated subarachnoid hemorrhage were
140 retrieved from the Premier Healthcare Database from 2010 to 2020 (Figure 2). The use of
141 fludrocortisone during this time increased gradually but remained less than 25%. For
142 intravenous therapy, saline was used in nearly 100% of the encounters. The use of balanced
143 crystalloids increased from 2010 to 2020, reaching the highest use (45%) in 2020.

144

145 **DISCUSSION**

146 Despite the recommendation by the 2023 (and in the previous 2012) American Heart
147 Association aSAH guidelines that “the use of mineralocorticoids is reasonable to treat
148 natriuresis and hyponatremia”(11) with a randomized level of evidence (Level B – Randomized)
149 and moderate strength of evidence (2a – moderate; Benefit >> Risk), the use of
150 mineralocorticoids in aSAH among the surveyed NINDS StrokeNet sites, which are largely
151 tertiary academic centers was 70%. Even more noteworthy is its use is less than 25% in real-
152 world practice data from Premier Healthcare Database. In the latter analysis, we did not include
153 hydrocortisone which has the second highest but non-significant mineralocorticoid activity
154 (relative potency of 0.008) compared to fludrocortisone (relative potency of 1)(13), because it is
155 also commonly used to treat other conditions and may not accurately capture our aim to
156 understand its use with the intent to treat natriuresis or hyponatremia. However, even with its
157 inclusion, the usage rate of mineralocorticoids in aSAH patients is relatively lower in real-world
158 practice compared to tertiary academic centers. Recent publications (14) suggest that
159 uncertainty regarding the benefits of fludrocortisone treatment on aSAH outcomes may be a
160 reason behind its low usage rates.

161 The usage rates of treatments of hyponatremia by the NINDS StrokeNet sites contrast
162 those reported in the survey of 32 neurosurgical units in the United Kingdom and Ireland (15). In
163 the latter survey, treatments used for hyponatremia were enteral salt supplementation (N=24,
164 75%), fluid restriction (N=18, 56.2%), hypertonic saline (N=17, 53.1%), and fludrocortisone
165 (N=7, 21.9%). Collectively, data from the United States, United Kingdom, and Ireland sites not
166 only demonstrate geographic variation in the treatment, but also commonly highlight the lack of
167 a protocol in the sites to treat hyponatremia. Among the NINDS StrokeNet sites, only 24
168 (27.6%) sites have a protocol. Similarly, only 9 (28.1%) of the surveyed sites in the United
169 Kingdom and Ireland have a protocol.

170 Maintaining intravascular volume is critical in aSAH patients, and crystalloid solutions
171 are recommended and most commonly used. However, the formulation which offers the best
172 outcomes for aSAH patients is unknown. Saline (0.9% NaCl) is the most commonly used
173 crystalloid. Several randomized controlled trials in general and specific ICU patients have shown
174 that balanced crystalloids, which have electrolyte composition similar to plasma, offer better
175 outcomes compared to saline (16, 17). In our analysis, we estimated the usage rates of two
176 balanced crystalloids—Plasma-Lyte or lactated Ringer’s—which are most commonly used. A
177 limitation of our data from the Premier Healthcare Database is the inability to assess which was
178 the primary fluid used since we captured the “order” for the fluid, not the quantity. Furthermore,
179 there are other formulations such as Normosol-R, Isolyte S, Ringer’s acetate, and Hartmann’s
180 solution whose usage rates we did not capture (18). Therefore, the collective usage rate of
181 balanced crystalloid is probably slightly higher than what we report. However, in the context of
182 increasing comparative effectiveness trials of balanced crystalloids versus saline, our data from
183 the Premier Healthcare Database are noteworthy for the increasing use of balanced crystalloids
184 in aSAH patients. Given their increase in usage, it is critical to study the impact of these
185 crystalloid formulations in aSAH patients because a considerable volume of crystalloids (>16
186 liters during the ICU stay) is given to them to maintain euvolemia (8-10). The volume given in
187 the randomized control trials pales in comparison. Meager evidence exists to inform crystalloid
188 selection in aSAH patients; one small study shows worse outcomes in aSAH patients with the
189 use of balanced crystalloids (8). Their increasing use in the United States is an important reason
190 to study the impact of different formulations of crystalloids used for intravenous fluid therapy.

191

192 **CONCLUSIONS**

193 Despite recommendations by the American Heart/Stroke Association guidelines, the use of
194 mineralocorticoids remains low, and balanced crystalloids are increasingly used as fluid therapy

195 in aSAH patients. If mineralocorticoids and balanced crystalloids improve outcomes of aSAH
196 patients must be rigorously tested.

197 **REFERENCES**

- 198 1. Chan V, Lindsay P, McQuiggan J, et al. Declining Admission and Mortality Rates for
199 Subarachnoid Hemorrhage in Canada Between 2004 and 2015. *Stroke* 2019;50:181-184.
- 200 2. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in
201 subarachnoid hemorrhage: the HAIR score. *Neurocrit Care* 2014;21:14-19.
- 202 3. Stienen MN, Germans M, Burkhardt JK, et al. Predictors of In-Hospital Death After
203 Aneurysmal Subarachnoid Hemorrhage: Analysis of a Nationwide Database (Swiss SOS [Swiss
204 Study on Aneurysmal Subarachnoid Hemorrhage]). *Stroke* 2018;49:333-340.
- 205 4. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid
206 haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol*
207 2009;8:635-642.
- 208 5. Chen S, Li Q, Wu H, et al. The harmful effects of subarachnoid hemorrhage on extracerebral
209 organs. *Biomed Res Int* 2014;2014:858496.
- 210 6. Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and
211 why? *Crit Care* 2015;19:309.
- 212 7. Solenski NJ, Haley EC, Jr., Kassell NF, et al. Medical complications of aneurysmal
213 subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants
214 of the Multicenter Cooperative Aneurysm Study. *Crit Care Med* 1995;23:1007-1017.
- 215 8. Mistry AM, Magarik JA, Feldman MJ, et al. Saline versus Balanced Crystalloids for Adults
216 with Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial. *Stroke*
217 *Vasc Interv Neurol* 2022;2.
- 218 9. Mistry AM, Mistry EA, Ganesh Kumar N, et al. Corticosteroids in the Management of
219 Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.
220 *Cerebrovasc Dis* 2016;42:263-271.

- 221 10. Barlow B, Thompson Bastin ML, Shadler A, et al. Association of chloride-rich fluids and
222 medication diluents on the incidence of hyperchloremia and clinical consequences in
223 aneurysmal subarachnoid hemorrhage. *J Neurocrit Care* 2022;15:113-121.
- 224 11. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With
225 Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart
226 Association/American Stroke Association. *Stroke* 2023;54:e314-e370.
- 227 12. Oddo M, Poole D, Helbok R, et al. Fluid therapy in neurointensive care patients: ESICM
228 consensus and clinical practice recommendations. *Intensive Care Med* 2018;44:449-463.
- 229 13. Schimmer BP, Funder JW. Adrenocorticotrophic Hormone, Adrenal Steroids, and the Adrenal
230 Cortex. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. *Goodman & Gilman's: The*
231 *Pharmacological Basis of Therapeutics*, 13e. New York, NY: McGraw-Hill Education, 2017.
- 232 14. Busl KM, Rabinstein AA. Prevention and Correction of Dysnatremia After Aneurysmal
233 Subarachnoid Hemorrhage. *Neurocrit Care* 2023.
- 234 15. Tominey S, Baweja K, Woodfield J, et al. Investigation and management of serum sodium
235 after subarachnoid haemorrhage (SaSH): a survey of practice in the United Kingdom and
236 Republic of Ireland. *Br J Neurosurg* 2021:1-4.
- 237 16. Collins MG, Fahim MA, Pascoe EM, et al. Balanced crystalloid solution versus saline in
238 deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised,
239 controlled trial. *Lancet* 2023;402:105-117.
- 240 17. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill
241 Adults. *N Engl J Med* 2018;378:829-839.
- 242 18. Semler MW, Kellum JA. Balanced Crystalloid Solutions. *Am J Respir Crit Care Med*
243 2019;199:952-960.
- 244

245 **FIGURE LEGENDS**

246

247 **Figure 1. Results of NINDS StrokeNet Sites' survey, assessing their intensive care unit**
248 **characteristics, hyponatremia treatments used, and types of fluids used to maintain**
249 **intravascular volume in aneurysmal subarachnoid hemorrhage patients.**

250

251

252 **Figure 2. Fludrocortisone and crystalloids usage rates in subarachnoid hemorrhage**
253 **patients in the Premier Healthcare Database.** From 2010 to 2020, 20,699 subarachnoid
254 hemorrhage encounters were retrieved across about 350 hospitals in the United States with a
255 CPT code involved in treating the ruptured aneurysm. The number above the dot indicates the
256 actual number of encounters.

Response Unresponsive No Yes



